News | March 29, 2022
USFDA approves EUA for second booster dose of Moderna
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Subscribe To Our Newsletter & Stay Updated
